XYRA Announces First Patient Dosed in Europe in the Phase 2/3 HARBOR-AF Study of Budiodarone in Paroxysmal and Persistent Atrial Fibrillation
LOS ALTOS, California, Aug. 31, 2026 (GLOBE NEWSWIRE) — Open-label, dose-escalation study using cardiac rhythm data from implantable and wearable AF monitors allows the treating physician to titrate the dose of budiodarone monthly. First European patient dosed in CLN-209 (HARBOR-AF) Study is the first to titrate an antiarrhythmic drug against continuously monitored AF burden (AFB) […]
We haven't written up this one. Financial Post has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.
